SALARIUS PHARMACEUTICALS, LLC RESTRICTED UNIT AWARD AGREEMENTRestricted Unit Award Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Texas
THIS RESTRICTED UNIT AWARD AGREEMENT (this “Agreement”) is dated as of January 21, 2017 (the “Grant Date”), by and between Salarius Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Scott Jordan (the “Grantee”).
SALARIUS PHARMACEUTICALS, LLC MANAGER AGREEMENTManager Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Delaware
This Manager Agreement (this “Agreement”) is made effective as of January 21, 2017 (the “Effective Date”) by and between Salarius Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”) and Sunil Sharma (the “Manager”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is entered into as of February 05, 2019 and effective as of December 15, 2018 (the “Effective Date”), by and between Salarius Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and David J. Arthur (the “Executive”), an individual residing at the address set forth on the signature page below.
Pharmaceutical License Agreement SP-2577 Salarius Pharmaceuticals, LLC and HLB LifeScience Co., LTD November 25, 2016Pharmaceutical License Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Delaware
This AGREEMENT dated as of November 25, 2016 (“Effective Date”) is made by and between Salarius Pharmaceuticals, LLC, a Delaware limited liability company, having its principal place of business at JLABS at Texas Medical Center, 2450 Holcombe Blvd., Suite J, Houston, Texas, 77021, United States of America (“SALARIUS”) and HLB LifeScience Co., LTD., having offices at A-602, JNK Digital Tower, 111, Digital-ro 26-gil, Guro-gu, Seoul, the Republic of Korea (“HLBLS”).
SALARIUS PHARMACEUTICALS, LLC RESTRICTED UNIT AWARD AGREEMENTRestricted Unit Award Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Texas
THIS RESTRICTED UNIT AWARD AGREEMENT (this “Agreement “) is dated as of August 1, 2016 (the “Grant Date”), by and between Salarius Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and David J. Arthur (the “Grantee”).
INDEX TO PATENT AND KNOW HOW EXCLUSIVE LICENSE AGREEMENT BETWEEN NUPOTENTIAL, INC. AND SALARIUS PHARMACEUTICALS, LLCPatent and Know-How Exclusive License Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Texas
This Agreement is effective as of the 18th day of December, 2018 (the EFFECTIVE DATE), between Salarius Pharmaceuticals, LLC, a Delaware limited liability company, with offices located at 2450 Holcombe Blvd., Ste. J-608, Houston, TX 77021 USA (LICENSEE), and NuPotential, Inc., a Delaware incorporated company, with offices located at Louisiana Emerging Technology Center, 340 E. Parker Blvd., Baton Rouge, LA 70803 (NUPOTENTIAL).
EXCLUSIVE LICENSE AGREEMENT dated August 3, 2011 between SALARIES PHARMACEUTICALS, LLC and UNIVERSITY OF UTAH RESEARCH FOUNDATIONExclusive License Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Utah
THIS LICENSE Agreement (“Agreement”) is entered into this third day of August, 2011 by and between the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah non-profit corporation, having its principal place of business at 615 Arapeen Drive, Suite 310, Salt Lake City, UT 84108, hereinafter referred to as “Licensor,” and SALARIUS PHARMACEUTICALS, LLC, having its principal place of business at 1740 South Morgantown Road, Greenwood, IN 46143, hereinafter referred to as “Licensee.”
ROYALTY AGREEMENTRoyalty Agreement • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Massachusetts
THIS ROYALTY AGREEMENT (the “Agreement”) is entered into as of January , 2019 (the “Effective Date”), by and among FLEX INNOVATION GROUP LLC, a Delaware limited liability company, having offices at 800 Boylston Street, 24th Floor, Boston, MA 02199 (the “Company”), Bruce Bean, an individual with an address of ***** (“Bean”), Donald MacKinnon, an individual with an address of ***** (“D. MacKinnon”), Roderick MacKinnon, an individual with an address of ***** (“R. MacKinnon,” and together with Bean and D. MacKinnon, the “Scientific Founders”) and Christoph Westphal, an individual with an address of ***** (“Westphal,” and together with the Scientific Founders, the “Founders”). Each of Company, Bean, D. MacKinnon, R. MacKinnon and Westphal may be referred to in this Agreement as a “Party” and collectively as the “Parties.”
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission.Cancer Research Grant Contract • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Salarius Pharmaceuticals LLC, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
